Amevive “complete response” letter
Biogen receives "complete response" letter for its antipsoriatic therapy Amevive (alefacept) on June 6. The letter asks for further "clarification and information" related to Amevive data already submitted by Biogen. Firm will not be required to conduct additional studies for approval, despite request for additional examination of Amevive safety profile in multi-cycle therapy by an FDA advisory committee. The committee voted 8-2 with one abstention for approval in moderate to severe psoriasis May 23 (1"The Pink Sheet" June 3, p. 22)...
You may also be interested in...
Biogen will distinguish Amevive in the psoriasis market by emphasizing the biologic's duration of response following FDA approval Jan. 30
The large pool of unsatisfied psoriasis patients means that the early uptake of Biogen's Amevive will not hinge on reimbursement issues, the company maintained during a July 18 conference call
Additional examination of multi-course therapy with Biogen's antipsoriatic Amevive should be conducted to create a more robust picture of long-term risk, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee suggested May 23